Difference between revisions of "Amitriptyline-moclobemide"

From Psychiatrienet
Jump to: navigation, search
(Created page with '{{Drugswitch | from = amitriptyline | to = moclobemide | stop = * '''Day 0:''' gradually reduce dosage of amitriptyline to a maximum of 50-100 mg/ day, when this dosage is > ...')
(No difference)

Revision as of 18:57, 3 May 2009

Amitriptyline
Type Antidepressant
Group TCA
links
ATC-code N06AA09
Medscape Amitriptyline
PubChem 2160
PubMed Amitriptyline
Kompas (Dutch) Amitriptyline
Wikipedia Amitriptyline
Moclobemide
Type Antidepressant
Group MAO-I
links
Medscape Moclobemide
PubChem 4235
PubMed Moclobemide
Kompas (Dutch) Moclobemide
Wikipedia Moclobemide

Switch medication from amitriptyline to moclobemide.[1] [2]

Nietinrijdenbord.png Stop amitriptyline
  • Day 0: gradually reduce dosage of amitriptyline to a maximum of 50-100 mg/ day, when this dosage is > 100 mg/day.
  • Day 1-7: reduce dosage of amitriptyline to 25-50 mg/day.
  • Day 8: stop administration of amitriptyline.
Eenrichtingbord.png Start moclobemide
  • Day 8-14: a wash-out period of one week is necessary.
  • Day 15: start administration of moclobemide in a dosage of 150 mg/day.
  • Day 18: increase dosage of moclobemide to 300 mg/day.


  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.